Seiya Yokoyama
Overview
Explore the profile of Seiya Yokoyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
710
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saito S, Yoshino H, Yokoyama S, Tominaga M, Li G, Arima J, et al.
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40004241
Recently, immune checkpoint inhibitors (ICIs) and cabozantinib, a tyrosine kinase inhibitor (TKI), have been used to treat renal cell carcinoma (RCC); the combination of these agents has become a standard...
2.
Hamada T, Yokoyama S, Akahane T, Matsuo K, Kitazono I, Furukawa T, et al.
Curr Issues Mol Biol
. 2025 Feb;
47(2).
PMID: 39996812
Electroporation is an efficient method for nucleotide and protein transfer, and is used for clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (Cas9)-mediated genome editing. In this study, we...
3.
Kirishima M, Yokoyama S, Akahane T, Higa N, Uchida H, Yonezawa H, et al.
Sci Rep
. 2024 Oct;
14(1):24955.
PMID: 39438642
Glioblastomas (GBMs) are the most aggressive types of central nervous system tumors. Although certain genomic alterations have been identified as prognostic biomarkers of GBMs, the histomorphological features that predict their...
4.
Higa N, Akahane T, Kirishima M, Yonezawa H, Makino R, Uchida H, et al.
Pathol Res Pract
. 2024 Oct;
263:155598.
PMID: 39357189
Previously, we constructed a DNA-based next-generation sequencing (NGS) panel for an integrated diagnosis of gliomas according to the 2021 World Health Organization classification system. The aim of the current study...
5.
Yoshimura T, Hirano Y, Hamada T, Yokoyama S, Suzuki H, Takayama H, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539521
Major advances have been made in cancer treatment, but the prognosis for elderly cancer patients with sarcopenia and frailty remains poor. Myokines, which are thought to exert preventive effects against...
6.
Yokoyama S, Matsuo K, Tanimoto A
Methods Mol Biol
. 2024 Feb;
2763:259-268.
PMID: 38347417
Methylation of CpG sites in the promoter region of genomic DNA is an important epigenetic modification that plays a critical role in gene regulation, particularly in gene silencing. Epigenetic abnormalities,...
7.
Kitazono I, Akahane T, Yokoyama S, Kubota E, Nishida-Kirita Y, Noguchi H, et al.
In Vivo
. 2023 Dec;
38(1):321-333.
PMID: 38148087
Background/aim: Among the four genomic subtypes of endometrial cancer, distinguishing between the DNA polymerase epsilon mutation (POLEmut) and no specific molecular profile (NSMP) subtypes requires genomic profiling owing to the...
8.
Higashi Y, Nakamura K, Takaoka R, Tani M, Noma Y, Mori K, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568586
MicroRNAs (miRNAs) have attracted attention as non-invasive cancer biomarkers in various cancers; however, they have not been adequately investigated in oral squamous cell carcinoma (OSCC). This study investigated the diagnostic...
9.
Higa N, Akahane T, Yokoyama S, Makino R, Yonezawa H, Uchida H, et al.
Neurooncol Adv
. 2023 Aug;
5(1):vdad078.
PMID: 37528810
Background: promoter () mutations are a biological marker of glioblastoma; however, the prognostic significance of mutational status is controversial. We evaluated this impact by retrospectively analyzing the outcomes of patients...
10.
Kitazono I, Akahane T, Yokoyama S, Kobayashi Y, Togami S, Yanazume S, et al.
Pathol Res Pract
. 2023 May;
247:154563.
PMID: 37229919
Endometrial cancers are classified into mismatch repair (MMR) deficient- (MMRd), p53 mutation- (p53mut), DNA polymerase epsilon (POLE) mutation (POLEmut), and no specific molecular profile (NSMP) subtypes according to The Cancer...